Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: The present disclosure relates to a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, and particularly to a pharmaceutical composition which exhibits a dual release profile of immediate release and sustained release so that long-term efficacy can be sustained. The pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, according to the present disclosure, can secure bioavailability equivalent to that of existing esomeprazole immediate-release/enteric-release formulations, and can maintain long-term efficacy due to the dual release profile thereof even when administered once a day, thus preventing the occurrence of nocturnal acid breakthrough, and accordingly, can be effectively used as a therapeutic agent for nocturnal acid breakthrough.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: Provided is a method of preparing a physiologically active polypeptide conjugate, in which a physiologically active polypeptide and a non-peptidyl polymer are linked to each other via a covalent bond. The method is to improve an overall yield of the physiologically active polypeptide conjugate by improving a reaction of the non-peptidyl polymer and the physiologically active polypeptide, and particularly, the method is to prepare a physiologically active polypeptide conjugate in a high yield by performing a two-step reaction through selective precipitation. The preparation method of the present invention is used to produce a non-peptidyl polymer-physiologically active polypeptide conjugate and a physiologically active polypeptide-physiologically active carrier conjugate in a high yield, and therefore, the method may be used in the development of long-acting formulations of various peptide drugs which maintain in vivo activity at a relatively high level and have remarkably increased blood half-life.

Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.

Abstract: The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.

Abstract: Provided is a Maxwellian view display which uses a space-time multiplexing scheme and widens a field of view, thereby having a degree of freedom within a set area instead of a fixed position while maintaining the advantage of the existing Maxwellian view, in which a clear image can be observed irrespective of the difference in individual ability for focal point adjustment since the focal point does not need to be adjusted. According to an embodiment of the present invention, a display includes: a light source unit for changing the position of a point light source according to time; a first lens for converting the light emitted from the light source unit to be parallel; an image generating unit for generating an image using the parallel light incident from the first lens; and a second lens for focusing the image generated by the image generating unit.

Abstract: A method for inserting information into a 3D structure and recognizing information in a non-destructive method is provided. A 3D printing method according to an exemplary embodiment of the present invention includes: generating a tag having specific information recorded thereon to be inserted into a 3D structure, and printing the tag on the inside of the 3D structure while printing the 3D structure. Accordingly, since the tag having information recorded thereon is printed on the inside of the 3D structure when the 3D structure is printed by a 3D printer, it is impossible to forge/falsify information.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: Provided are a system and a method for displaying content in association with a position of a projector. A method for displaying an image, according to one embodiment of the present invention, comprises identifying a position of an image output device, generating a partial image from a full image on the basis of the position of the image output device, and outputting the generated partial image by means of the image output device. As a result, since the image projected from the image output device changes in association with the position of the image output device, a more realistic AR/VR may be provided.

Abstract: A liquid crystal display includes: a first insulation substrate; a gate line disposed on the first insulation substrate; a first data line and a second data line disposed on the first insulation substrate; a color filter disposed on the first insulation substrate and disposed between the first data line and the second data line; a first light blocking member disposed on the first data line and the second data line; and a second light blocking member disposed on the color filter and the first light blocking member, extending in the same direction as the gate line, and overlapping the first light blocking member on the first data line and the second data line.

Abstract: The present invention relates to a rope for an elevator. The rope for the elevator comprises: a center strand formed by twisting a plurality of wires; inner layer strands formed by twisting the plurality of wires and arranged along the outer periphery of the center strand; and outer layer strands formed by twisting the plurality of wires and arranged along the outer periphery of the inner layer strands, wherein ten of each of the inner layer strands and the outer layer strands are prepared, the diameter of the center strand, the diameter of the inner layer strand and the diameter of the outer layer strand are respectively 0.33-0.35 times, 0.13-0.15 times and 0.22-0.24 times as large as the diameter of a first imaginary circle circumscribed around the outer layer strands, and a fill factor is 64-67%.

Abstract: Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.

Abstract: A laser light source shutter system includes a light source, a variable focus optical element to transmit a beam emitted from the light source, a pinhole located on an optical path through which the beam travels from the variable focus optical element, and a controller to control a transmission and blocking of the beam by controlling a focal length of the variable focus optical element to be equal to a distance between the variable focus optical element and the pinhole or to be equal to other distances different from the distance. Therefore, a laser light source shutter free from vibration can be realized electronically with a low cost and a high light-blocking rate using a variable focus optical element such as a variable focus lens and a variable focus mirror.

Abstract: A plate laminated type heat exchanger includes: a plate laminated body which is formed by laminating a plurality of plates; and a heat exchanger body which includes a first header through which fluid (G) flows in from outside of the plate laminated body and a second header through which the fluid (G) flows out to the outside of the plate laminated body which are connected to the plate laminated body. Each of the plurality of plates is formed from a flat plate shape having a first surface and a second surface. The first surface is provided with a plurality of grooves defined by inner walls through which the fluid flows. The plurality of plates are connected each other so that the first surface of one of the plurality of plates is brazed to the second surface of the other one of the plurality of plates.

Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer containing pleiotropic regulator 1 (PLRG1) inhibitor as an active ingredient, a method for treating cancer including administering the composition to a subject, a composition for diagnosing cancer containing an agent for measuring the expression level of PLRG1, a method for providing information for diagnosing cancer including measuring the expression level of PLRG1, and a method for screening agents for preventing or treating cancer. Pleiotropic regulator 1 (PLRG1) is overexpressed in cancer cells, and the inhibition of the expression of PLRG1 can induce cancer cell-specific apoptosis. Accordingly, the PLRG1 inhibitor of the present invention has an excellent effect as an anticancer agent without side effects, and additionally, the PLRG1 inhibitor can be used for cancer diagnosis, screening of anticancer agents, etc. by measuring the expression levels of PLRG1.

Abstract: A liquid formulation of highly concentrated long-acting human growth hormone conjugate contains a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent. A method for preparing the same is provided.

Abstract: A curved display device including a first substrate, a thin film transistor (TFT) disposed on the first substrate, a pixel electrode connected to the TFT, a second substrate overlapping the first substrate, a liquid crystal layer disposed between the first and the second substrates, and a common electrode disposed between the second substrate and the liquid crystal layer, in which the pixel electrode includes a cross-shaped stem portion having a horizontal stem portion, a vertical stem portion, and a plurality of fine branches extending from the cross-shaped stem portion, at least one of the fine branches includes a first portion and a second portion having a width greater than that of the first portion, and an extending line from a boundary between the first portion and the second portion is sloped at an angle in a range of ?10 degrees to +10 degrees with respect to the vertical stem portion.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.